verapamil has been researched along with Parkinson Disease, Secondary in 3 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor." | 7.68 | Effect of ethosuximide on rest tremor in the MPTP monkey model. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF, 1992) |
| "Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor." | 3.68 | Effect of ethosuximide on rest tremor in the MPTP monkey model. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF, 1992) |
| " This seems to be a rare side effect as there have only been three other reported cases of secondary extrapyramidal syndromes in the literature." | 2.38 | [Parkinson syndrome, a possible adverse effect of calcium inhibitors]. ( Lauribe, P; Lévy, S; Malaterre, HR; Paganelli, F; Ramond, B, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Padrell, MD | 1 |
| Navarro, M | 1 |
| Faura, CC | 1 |
| Horga, JF | 1 |
| Malaterre, HR | 1 |
| Lauribe, P | 1 |
| Paganelli, F | 1 |
| Ramond, B | 1 |
| Lévy, S | 1 |
| Gomez-Mancilla, B | 1 |
| Latulippe, JF | 1 |
| Boucher, R | 1 |
| Bédard, PJ | 1 |
1 review available for verapamil and Parkinson Disease, Secondary
| Article | Year |
|---|---|
[Parkinson syndrome, a possible adverse effect of calcium inhibitors].
Topics: Aged; Calcium Channel Blockers; Diltiazem; Female; Humans; Male; Parkinson Disease, Secondary; Verap | 1992 |
2 other studies available for verapamil and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Verapamil-induced parkinsonism.
Topics: Aged; Female; Humans; Hypertension; Parkinson Disease, Secondary; Vasodilator Agents; Verapamil | 1995 |
Effect of ethosuximide on rest tremor in the MPTP monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diltiazem; Dopamine Agents; Dose-Response Rel | 1992 |